Context: Studies of the possible cardiovascular risk of testosterone treatment are inconclusive.
Intervention: Testosterone gel, the dose adjusted to maintain the testosterone level in the normal range for young men, or placebo gel for 12 months.
Main Outcome Measures: Serum markers of cardiovascular risk, including lipids and markers of glucose metabolism, fibrinolysis, inflammation, and myocardial damage.
Results: Compared with placebo, testosterone treatment significantly decreased total cholesterol (adjusted mean difference, 26.1 mg/dL; P , 0.001), high-density lipoprotein cholesterol (adjusted mean difference, 22.0 mg/dL; P , 0.001), and low-density lipoprotein cholesterol (adjusted mean difference, 22.3 mg/dL; P = 0.051) from baseline to month 12. Testosterone also slightly but significantly decreased fasting insulin (adjusted mean difference, 21.7 mIU/mL; P = 0.02) and homeostatic model assessment-insulin resistance (adjusted mean difference, 20.6; P = 0.03). Testosterone did not change triglycerides, D-dimer, C-reactive protein, interleukin 6, troponin, glucose, or hemoglobin A1c levels more than placebo.
Conclusions and Relevance: Testosterone treatment of 1 year in older men with low testosterone was associated with small reductions in cholesterol and insulin but not with other glucose markers, markers of inflammation or fibrinolysis, or troponin. The clinical importance of these findings is unclear and requires a larger trial of clinical outcomes. (J Clin Endocrinol Metab 103: [681] [682] [683] [684] [685] [686] [687] [688] 2018) T he effect of testosterone treatment on cardiovascular risk is uncertain. Some retrospective studies using electronic medical records have reported more cardiovascular adverse events in men taking testosterone than in men not taking it, but others have not (1) (2) (3) (4) . These studies all have the limitations of not being controlled for diagnosis or treatment. One clinical trial of testosterone in frail older men was stopped early because more cardiovascular adverse events occurred in men taking testosterone than in men taking placebo (5) , but another similar trial reported few adverse cardiovascular events (6) . Meta-analyses of clinical trials have generally not shown more adverse cardiovascular events in men taking testosterone than in men taking placebo, but none of the individual trials was designed prospectively to capture these events (7, 8) .
The Testosterone Trials (TTrials) were a group of seven coordinated trials involving 788 men to determine the efficacy of raising the serum testosterone levels of men $65 years of age to normal levels for young men for 1 year (9) . Although the numbers of men who experienced major cardiovascular adverse events were similar in the two treatment arms in all men in the TTrials (10), testosterone treatment was associated with a greater increase in noncalcified coronary artery plaque volume by computed tomographic angiography in the 138 men who participated in the Cardiovascular Trial (11) .
If testosterone does affect cardiovascular risk, it might do so by altering any one of several cardiovascular risk factors, such as lipids, glucose metabolism, coagulation, and inflammation. We therefore measured several biomarkers of cardiovascular risk at baseline and after 3 and 12 months of treatment in all men participating in the TTrials.
Methods

Study design
The TTrials were a coordinated group of seven doubleblind placebo-controlled trials designed to evaluate the efficacy of testosterone treatment in men $65 years of age who had age-related low testosterone levels (9) . To participate in the TTrials, a man had to qualify for at least one of the three main trials (Sexual Function, Physical Function, and Vitality). Those who qualified could also participate in any of the other trials if they met the respective entry criteria. The participants were allocated to receive testosterone or placebo gel for 1 year. This report describes the serum levels of cardiovascular biomarkers at baseline and months 3 and 12 in all men participating in the TTrials.
The institutional review boards of the 12 participating sites approved the TTrials protocols. Before trial-related procedures were conducted, all participants provided written informed consent. An independent Data and Safety Monitoring Board oversaw participant safety and trial conduct.
Participants
The inclusion and exclusion criteria have been published (9) . In brief, men were included who were $65 years of age, had serum testosterone levels that averaged ,275 ng/dL in two morning samples, and had subjective and objective evidence of sexual dysfunction, physical dysfunction, and/or reduced vitality. Men were excluded if they were at moderate or high risk for prostate cancer; had a myocardial infarction within the previous 3 months; or had a blood pressure level .160 mm Hg systolic or 100 mm Hg diastolic, serum creatinine level .2.2 mg/dL, or a hemoglobin A1c (HbA1c) value .8.5%. Men who were taking medications to control blood pressure or serum lipid levels were not excluded.
Testosterone treatment
Men were allocated to receive either testosterone as a 1% gel in a pump bottle (testosterone gel, AndroGel; AbbVie, North Chicago, IL) or similar placebo gel in a double-blind fashion for 1 year. The initial dose of testosterone was 5 g a day. The dose was adjusted to keep the serum concentration within the normal range for young men on the basis of measurement in a central laboratory (Quest Clinical Trials, Valencia, CA) at months 1, 2, 3, 6, and 9. To maintain the blind, when the dose was changed in a man taking testosterone, the dose was also changed in a man taking placebo.
Assessments
Blood for cardiovascular biomarkers was drawn fasting in the morning at baseline and at months 3 and 12; serum was stored at 280°C. Biomarker assays were performed at the Laboratory for Clinical Biochemistry Research, University of Vermont, with the exception of the troponin I assay, which was performed at the University of Minnesota. Samples from the same participant were assayed in the same batch. Clinical variables were measured at baseline and months 3, 6, 9, and 12.
Lipid assays
Lipid assays included total cholesterol [interassay coefficient of variation (CV) range, 1.45% to 2.33%], high-density lipoprotein (HDL) cholesterol (interassay CV range, 1.69% to 2.26%), and triglycerides (interassay CV range, 1.95% to 2.57%) using enzymatic colorimetric assays (Cobas Integra 400; Roche Diagnostics, Indianapolis, IN). Low-density lipoprotein (LDL) cholesterol was calculated using the Friedewald formula when the triglyceride concentration was ,400 mg/dL.
Glucose, insulin, and HbA1c assays
Glucose concentration was determined using a hexokinase method (Cobas Integra 400, Roche Diagnostics) (interassay CV range, 2.24% to 4.55%). Insulin was measured by electrochemiluminescence immunoassay (Elecsys 2010; Roche Diagnostics) (interassay CV range, 2.39% to 2.78%). HbA1c was measured in frozen whole blood samples by turbidimetric inhibition immunoassay (Tina-quant HgA1C Gen 2 Whole Blood application, Cobas Integra 400; Roche Diagnostics) (interassay CV range, 1.63% to 3.25%).
Assays of markers of inflammation
C-reactive protein (CRP) was measured using a high-sensitivity particle enhanced immunonephelometric assay (BN II nephelometer; Siemens, Inc., Deerfield, IL) (interassay CV range, 3.32% to 4.64%). Interleukin (IL)-6 was measured by electrochemiluminescence immunoassay (Meso Scale Diagnostics, Rockville, MD) (interassay CV range, 8.14% to 11.95%).
D-dimer and troponin assays
D -dimer was measured using an immunoturbidimetric assay (STA-R Evolution, Diagnostica Stago, Parsippany, NJ) (interassay CV range, 2.73% to 20.14%). Troponin I was measured using a high-sensitivity immunoassay (ARCHITECT STAT high-sensitive troponin I assay; Abbott Laboratories, Abbott Park, IL).
Statistical analyses
The effects of testosterone were assessed using random effects models for longitudinal data. The models included visit time as a categorical variable and a single main effect for treatment and were adjusted for baseline values of each biomarker and all balancing variables used in the allocation procedure: study site, indicator variables of participation in each primary efficacy trial, baseline testosterone concentration (# or . 200 ng/dL), age (# or . 75 years), use of antidepressants, and use of phosphodiesterase-5 inhibitors. All participants who had at least one postbaseline value were included in the intent-totreat analysis. We performed additional analyses of lipid markers excluding men who were not taking lipid-lowering medications at baseline but initiated them during the study; we also performed separate analyses of metabolic markers excluding men taking antidiabetic medications. Significance was assessed through the two-sided Wald test and confidence interval for the treatment effect. The treatment effect denotes the average difference in response by treatment arm across all visits (baseline and months 3 and 12) . No adjustments were made for multiple testing.
Results
Participants and clinical measures
TTrials enrollment was 788 men at 12 sites. The mean age at baseline was 72 years. Relatively high percentages were obese and had comorbid conditions, such as diabetes and hypertension, but the two treatment arms were well balanced for these conditions and related medications (Table 1) . Testosterone treatment increased the serum testosterone concentration from unequivocally low at baseline to midnormal for young men by month 3 and maintained it at that level through month 12 (10) . Compared with placebo, testosterone treatment did not significantly change weight (adjusted difference, 0.28 kg; P = 0.18), body mass index (adjusted difference, 0.09 kg/m 2 ; P = 0.21), or waist/ hip ratio (adjusted difference, 0.002; P = 0.46) ( Table 2) .
Lipids
Serum concentrations of lipids (Table 3) were evaluated for all men and then separately for men who were Lipid levels decreased during the 12 months of treatment in both treatment arms. Adjusting for baseline levels and balancing factors, the men treated with testosterone had a reduction in total cholesterol that was 6.1 mg/dL greater than men treated with placebo (P , 0.001). Reductions in HDL cholesterol (adjusted difference, 22.0 mg/dL; P , 0.001) and in non-HDL cholesterol (adjusted difference, 24.2; P = 0.005) were also greater in men treated with testosterone than in men treated with placebo. Change in LDL cholesterol was marginally greater in the testosterone arm; the adjusted difference in change was 2.3 mg/dL (P = 0.051). Reductions in triglyceride values were not significantly associated with treatment assignment. Eleven men in the testosterone arm and four in the placebo arm initiated lipid-lowering medication after baseline. To assess the effect of these medication changes, we performed an analysis excluding these 15 men; the results changed minimally.
Markers of glucose metabolism
We evaluated markers that reflect glucose metabolism (Table 4) in all men and separately in men who were not taking medications for diabetes during the trial. Mean levels were similar in the two treatment groups at baseline [fasting glucose, 114.4 vs 116.0 mg/dL; fasting insulin, 18.6 vs 18.1 mU/mL; homeostatic model assessmentinsulin resistance (HOMA-IR), 5.8 vs 5.9; and HbA1c, 6.3% vs 6.3% in the testosterone and placebo arms, respectively]. Changes from baseline in these markers were small in both groups, but some differences in the changes between treatment arms were statistically significant (glucose, 1.3 vs 2.2 mg/dL; adjusted difference, 21.5 mg/dL; P = 0.30; insulin, 21.8 vs 20.7 mU/mL; adjusted difference, 21.7 mU/mL; P = 0.02; HOMA-IR, 0.3 vs 20.2; adjusted difference, 20.6; P = 0.03; and HbA1c, 0.0% vs 0.1%; adjusted difference 20.07%; P = 0.09 for men in the testosterone group vs the placebo group, respectively). Evaluation of these markers in men not taking antidiabetic medications showed no statistically significant effect of testosterone.
Other markers
We also measured D-dimer as a marker of fibrolysis, CRP and IL-6 as markers of inflammation, and troponin as a marker of myocardial damage (Table 5 ). All showed similar mean baseline values (D-dimer, 0.7 vs 0.7 mg/L; CRP, 3.5 vs 3.5 mg/L; IL-6, 1.9 vs 2.0 pg/mL; troponin, 7.6 vs 9.1 ng/L in the testosterone and placebo groups, respectively). Mean changes from baseline were small and were similar between the testosterone and placebo groups (D-dimer, 0.1 vs 0.1 mg/L; adjusted difference, 0.01; P = 0.69; CRP, 20.7 vs 20.1 mg/L; adjusted difference, 20.6 mg/L; P = 0.11; IL-6, 0.9 vs 0.2 pg/mL; adjusted difference, 0.2 pg/mL; P = 0.67; and troponin, 2.4 vs 0.1 ng/mL; adjusted difference, 0.9 mg/L; P = 0.37).
Because testosterone treatment was associated with a greater increase in coronary artery plaque volume in the 138 men who participated in the Cardiovascular Trial (11), we repeated all the analyses of the effects of testosterone in just the 138 men who participated in the Cardiovascular Trial. The results in these 138 men were similar to the results in all TTrials participants.
Discussion
In the TTrials, raising the serum testosterone concentrations of men $65 years of age who had low baseline testosterone values to normal levels for young men for 1 year did not affect weight, body mass index, or waist/ hip ratio but slightly decreased serum concentrations of total, HDL, and LDL cholesterol. The total cholesterol/ HDL cholesterol ratio was not altered. Testosterone treatment also slightly decreased markers of insulin resistance but did not change fasting glucose or HbA1c levels. Testosterone treatment did not appreciably change markers of inflammation, fibrinolysis, or myocardial damage.
Prior trials of the effects of injectable testosterone esters on serum lipid levels in hypogonadal men have also demonstrated small reductions in serum total, HDL cholesterol, and LDL cholesterol levels (12) . Metaanalyses of testosterone trials that included variable entry criteria for participants, routes of administration, and doses have shown inconsistent effects on cholesterol (8, 13) . In a double-blind crossover study of injectable testosterone vs placebo in 24 hypogonadal men with type 2 diabetes, testosterone treatment was associated with improved insulin sensitivity and glycated hemoglobin levels (14), but meta-analyses have generally not reported an effect of testosterone on glucose metabolism (8) . Several studies have shown no clear effects of testosterone treatment on various inflammatory markers (15) (16) (17) .
Compared with the effect of statin drugs on lowering LDL cholesterol, the effect of testosterone in this trial was quite small. Statin drugs, in doses used clinically, lower LDL cholesterol by 10 to 80 mg/dL (18) compared with the mean reduction of 2.3 mg/dL associated with testosterone treatment in this trial. Compared with the effect of statin drugs raising HDL cholesterol level, the effect of testosterone on lowering HDL cholesterol level is similar. Statin drugs, in doses used clinically, raise HDL cholesterol by 2 to 3 mg/dL (19) , similar in magnitude to the reduction of 2.0 mg/dL associated with testosterone treatment in this trial. Ingestion of 17-alkylated androgens, which are abused by athletes, decreases HDL cholesterol much more than testosterone itself (20) .
The results presented here are important because of the many strengths of the TTrials, including the large number of participants, the placebo-controlled design, raising the median serum testosterone level from unequivocally low to midnormal for young men, and the excellent participant retention. One limitation of this trial is that the results apply only to older men with low testosterone. Another limitation is that all of the cardiovascular markers assessed were surrogates and not clinical outcomes. Yet another limitation is that we did not assess the function of the lipoproteins, such as the effect of HDL on cholesterol transport (21) .
The clinical significance of the decreases in cholesterol levels is uncertain because both LDL and HDL cholesterol levels fell, both to small degrees, and insulin and HOMA-IR levels fell but only slightly. In the 138 men in the TTrials who underwent computed tomography angiography at baseline and month 12, testosterone treatment was associated with a greater increase Values are means 6 standard number (number).
Abbreviations: BMI, body mass index; CI, confidence interval. a Average over all observations, adjusting for balancing factors and baseline value. Positive values mean men in the testosterone arm increased more or decreased less than men in the placebo arm; negative values mean men in the placebo arm increased more or decreased less than men in the testosterone arm.
in noncalcified coronary artery plaque volume than placebo treatment, yet in all TTrials participants, a similar number of men (seven) in each treatment arm experienced major adverse cardiovascular events (10) . A trial of a much larger number of men treated for a much longer time is necessary to determine whether testosterone treatment of hypogonadal men affects clinical cardiovascular risk. We concluded that raising the serum testosterone levels of men $65 years of age with low testosterone to normal levels for young men slightly decreased their serum cholesterol and insulin levels, but the clinical significance of these small decreases is unknown.
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